In the past decade, targeting of the PD-1/PD-L1 checkpoint, with or without CTLA-4 targeting, has revolutionized cancer treatment. However, a significant proportion of patients with lung cancer still do not benefit from these advances. In the patients who benefit most, the expression of PD-L1 in the tumor is, in general, high.1 An effective immune response…

Despite the past decade’s accomplishments in identifying the genetic drivers of NSCLC, the complexity of these cancers continues to create barriers to effective targeted treatment. Finding strategies capable of overcoming those barriers will depend, in part, on the in-depth study of the proteins whose activity causes oncogenicity, according to Ramaswamy Govindan, MD, a medical oncologist…

Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the preferred initial therapy. A growing body of evidence suggests fusions in NRG1 (neuregulin 1) will emerge as yet another relevant genomic target. NRG1 fusions are rare events, present across tumor types…

Not all published papers are on equal footing.

The ILCN is aware that the situation with telehealth differs across regions and that lack of access to technology is a huge obstacle. We would love to hear from IASLC members around the globe about your experiences. Please email us at [email protected].

Surgical resection is the most effective treatment for patients with early-stage NSCLC.1 However, approximately 25% of these patients do not undergo resection, usually because of underlying comorbidities precluding surgery or because of patient refusal.2 For these patients and others with medically inoperable conditions, several guidelines recommend stereotactic body radiotherapy.3 However, the indication of stereotactic body…

CheckMate-816 made quite a splash at both the AACR Annual Meeting 2021 and the 2021 ASCO Annual Meeting’s virtual podium, and the accompanying article by Patrick Forde, MD, explains why. Dr. Forde, who is director of the Thoracic Oncology Clinical Research Program and associate professor of Oncology at Johns Hopkins Medicine in Baltimore, MD, met…